Mineralocorticoid antagonists and ENaC inhibitors in hyperaldosteronism

Hyperaldosteronism (HA) due to nodular adrenal cortical hyperplasia or adrenal adenoma is increasingly recognized as a major cause of resistant or refractory hypertension.1 HA is the most common form of secondary hypertension (HTN), with an estimated prevalence of 4% of hypertensive patients in primary care and around 10% of patients referred to hypertension specialty clinics.1 Patients with HA have higher cardiovascular (CV) disease morbidity...